Skip to content

Study on the intervention and management model of metabolic syndrome complicated with hyperuricemia based on ''state'' identification --Study on comprehensive intervention in acute stage of metabolic syndrome complicated with gout

Study on the intervention and management model of metabolic syndrome complicated with hyperuricemia based on ''state'' identification --Study on comprehensive intervention in acute stage of metabolic syndrome complicated with gout

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2022000046
Enrollment
Unknown
Registered
2022-06-30
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome\Gout

Interventions

None:None

Sponsors

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of gouty arthritis and metabolic syndrome in western medicine; (2) It conforms to the standard of "dampness heat stasis syndrome" in TCM; (3) Acute course of disease, the time from this attack to treatment is within 1 week; (4) The patient is over 18 years old; (5) After full notification, the patient is willing to cooperate with relevant diagnosis and treatment and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Secondary hyperuricemia and Gout Caused by some systemic diseases or drugs, such as myeloproliferative diseases and gouty arthritis caused by diuretics; (2) The patient's affected joints were complicated with serious fracture, trauma, traumatic arthritis and other diseases, which affected the curative effect; (3) Gout has caused severe deformity of affected joints or skin ulceration, affecting the functional judgment and external drug users; (4) The patient has received or is receiving uric acid lowering treatment, such as oral febusitar, benzbromarone, allopurinol and other drugs; (5) Patients who are known to be allergic or intolerant to the drugs used for treatment; (6) Patients with severe cardiovascular, cerebrovascular, blood system, immune system, mental system and other diseases, liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Blood uric acid;

Secondary

MeasureTime frame
Blood pressure;erythrocyte sedimentation rate;cholesterol;Low density lipoprotein;Fasting blood glucose;Blood creatinine;High density lipoprotein;triglyceride;Postprandial blood glucose;C-reactive protein;Urea nitrogen;

Countries

China

Contacts

Public ContactChen Liang

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine

chenliang728128@qq.com13683389984

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026